Drug intelligence / Profile preview

trivalent DNA influenza vaccine

Development stage: Phase 1
Lead developer: Pfizer
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Particle Mediated Epidermal Delivery

Overview

The trivalent DNA influenza vaccine is a biological intervention designed to prevent influenza. It is administered via Particle Mediated Epidermal Delivery (PMED) and aims to induce an antibody response in the body. The vaccine targets specific influenza strains: A/New Caledonia/20/99, A/Panama/2007/99, and B/Jiangsu/10/20. Its purpose is to evaluate its effectiveness in preventing flu symptoms after direct exposure to the influenza virus, as well as its tolerability and ability to produce antibody responses.

Other names: Trivalent DNA vaccine

Targets

Neuraminidase

Beyond the preview

Go deeper on trivalent DNA influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trivalent DNA influenza vaccine.

Explore the full profile